Navigation Links
Cardium Reports on First Quarter 2008 Highlights and Financial Results
Date:5/9/2008

ovascular cooling system during

brain surgery at Stanford University. The segment (episode 5) is

scheduled to be rebroadcast tonight, May 9, at 8:30 p.m. and 11:30 p.m.

(ET/PT).

Financial Report

For the quarter ended March 31, 2008, the Company reported a net loss of $6.7 million, or $0.16 per share, which included research and development costs totaling $3.4 million and selling, general and administrative expenses of $3.4 million. Non-cash charges relating to stock-based compensation, depreciation and amortization for the first quarter of fiscal 2008 totaled $906,000. Total revenue for the first quarter 2008 was $646,000, compared to $309,000 for the same quarter last year. The increase in revenue was a result of an increase in InnerCool sales resulting from our expanded sales and marketing efforts. Cash and cash equivalents as of March 31, 2008 were $6.3 million.

About Cardium

Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc. and the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic and related indications. Cardium's lead product candidate, Generx (alferminogene tadenovec, Ad5FGF-4), is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. For more information about Cardium Therapeutics and its businesses, products and therapeutic candidates, please visit http://www.cardiumthx.com or view its 2007 Annual Report at http://www.cardiumthx.com/flash/pdf/CardiumAR07_Book_FINAL.
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
2. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
3. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
4. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
5. Cardium Completes $5.3 Million Registered Direct Offering
6. Cardium Announces $5.3 Million Registered Direct Offering
7. Novavax Reports First Quarter 2008 Financial Results
8. Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
9. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results
10. Pharmos Corporation Reports 2008 First Quarter Results
11. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... 14 The third edition of ... , published by the Infusion Nurses Society ... anthracycline extravasation.(1) Anthracyclines are a group of ... that have been used in the treatment of ... ,, According to the INS publication: ...
(Date:12/14/2009)... Decision Resources, one of the world,s ... healthcare issues, finds that, owing to the launches ... market will increase more than sevenfold from $790 ... in the United States, France, Germany, Italy, Spain, ... Pharmacor report entitled Atrial Fibrillation finds ...
(Date:12/11/2009)... -- Dendreon Corporation (Nasdaq: DNDN ) announced ... public offering have exercised in full their option ... stock at the public offering price of $24.75 ... increases the size of the offering to an ... Dendreon expects to receive net proceeds from the ...
(Date:12/11/2009)... Ambit Biosciences Corporation announced today the enrollment ... Anderson Cancer Center of the first patient in the ... E fficacy) Phase 2 pivotal trial in patients ... AC220 is a novel, orally available, potent and highly ... FMS-like tyrosine kinase-3 (FLT3) inhibitor. The ACE study ...
Breaking Biology Technology:Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5
... Benson may be as different as, well, New York City ... entrepreneurs, including those operating in the technology space. , ,Their ... see, but the result may be a largely untapped source ... business to the next level. Specifically, the million-dollar level. ...
... for the White Sox this year and as for ... until next year." What we cannot "wait until next year" for ... for all of Chicago. , ,There should be as much buzz, ... there is on teams that didn't even make the playoffs, but ...
... - The dizzying pace of change sparked by ... solutions abound to almost every business challenge, but has ... anecdotal evidence collected at a recent Wisconsin technology conference, ... presented by Paragon Development Systems , brought together ...
Other Biology Technology:Women entrepreneurs reach for $1M level 2Women entrepreneurs reach for $1M level 3Wait `till next year OK for baseball, not broadband 2Wait `till next year OK for baseball, not broadband 3Wait `till next year OK for baseball, not broadband 4Wait `till next year OK for baseball, not broadband 5Are businesses getting what they need from IT? 2Are businesses getting what they need from IT? 3
(Date:12/11/2009)... Malus orientalis species of wild apples that could be ... Middle East and Central Asia. A new study comparing ... varieties from Georgia and Armenia with previously collected varieties ... and establishes a core collection that will make ... research communities. , To identify and record the genetic ...
(Date:12/11/2009)... does a cell manage to identify and degrade the ... body against serious diseases? The researchers Sabine C. Horn, ... Jarosch of the Max Delbrck Center for Molecular Medicine ... in this puzzle. In an enzyme complex that plays ... they discovered a scaffold regulating the identification and disposal ...
(Date:12/11/2009)... release is available in French . ... discovered a novel molecular mechanism that prevents cancer. In ... Molecular Cell , scientists from the Universit de Montral ... that the SOCS1 molecule prevents the cancer-causing activity of ... diseases such as Crohns, in smokers and people exposed ...
Breaking Biology News(10 mins):Understanding apples' ancestors 2MDC researchers identify a scaffold regulating protein disposal 2Scientists identify natural anti-cancer defenses 2Promising hematologists begin year long program to pursue careers in clinical research 51517 1Promising hematologists begin year long program to pursue careers in clinical research 51517 2Grant encourages protected research time for medical fellows 51515 1Queens University study aims at early diagnosis for ADHD and Parkinsons disease 51513 1Queens University study aims at early diagnosis for ADHD and Parkinsons disease 51513 2
... argued about how birds evolved the ability to fly, ... fitness would result from ancestral, partly evolved wings. Two ... flight evolved in tree-dwelling ancestors that used their forelimbs ... birds to be terrestrial dinosaurs that developed powered flight ...
... largest HIV/AIDS therapy studies conducted to date show ... more than doubles the risk of AIDS or ... Mailman School of Public Health and Harlem Hospital ... as Strategies for Management of Anti-Retroviral Therapies, or ...
... the infection rate of three viruses ?and risk of death ... be reported in the Nov. 1 print edition of Nature ... Medicine, The Methodist Hospital, and Texas Children's Hospital. , ... phase 1 trial, funded by the National Heart, Lung, and ...
Other Biology News:Protowings may have helped bird ancestors cover rough terrain 2Study shows interruption of antiretroviral therapy increases risk of disease and death 2Study shows interruption of antiretroviral therapy increases risk of disease and death 3Three-in-one virus killer prevents common, often fatal infections 2
...
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
Carrier-Free Recombinant Human Flt-3/Flk-2 Ligand (Flt3/Flk2 Ligand, Flt3L, Flt3-L, Flk2L, Flk2-L) 100 ug...
Anti-CD74 Monoclonal Antibody Description: 200 l Research Focus: cell surface antigens Storage: 4C Shipping Temperature: 4C...
Biology Products: